Evolus, Inc. (NASDAQ:EOLS - Get Free Report) Director Karah Herdman Parschauer sold 12,888 shares of the business's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $12.99, for a total transaction of $167,415.12. Following the sale, the director now directly owns 32,183 shares of the company's stock, valued at $418,057.17. This represents a 28.59 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Evolus Stock Down 2.3 %
Shares of NASDAQ:EOLS traded down $0.31 during trading hours on Tuesday, reaching $13.28. The stock had a trading volume of 732,358 shares, compared to its average volume of 594,055. Evolus, Inc. has a 1 year low of $9.25 and a 1 year high of $17.82. The firm's 50 day moving average is $13.19 and its 200-day moving average is $13.94. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47. The stock has a market capitalization of $844.44 million, a price-to-earnings ratio of -14.59 and a beta of 1.28.
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the stock. KBC Group NV purchased a new position in shares of Evolus in the 4th quarter valued at $49,000. IFP Advisors Inc grew its position in shares of Evolus by 17,440.7% in the 4th quarter. IFP Advisors Inc now owns 4,736 shares of the company's stock valued at $52,000 after buying an additional 4,709 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new position in Evolus during the 4th quarter worth $106,000. Rafferty Asset Management LLC purchased a new position in Evolus during the 4th quarter worth $115,000. Finally, Quantbot Technologies LP purchased a new position in Evolus during the 4th quarter worth $118,000. 90.69% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
EOLS has been the subject of several research reports. Barclays upped their price objective on shares of Evolus from $22.00 to $25.00 and gave the company an "overweight" rating in a research note on Wednesday, March 5th. HC Wainwright reissued a "buy" rating and issued a $27.00 price target on shares of Evolus in a research note on Wednesday, March 5th. Finally, Needham & Company LLC restated a "buy" rating and issued a $22.00 price objective on shares of Evolus in a report on Wednesday, March 5th.
View Our Latest Analysis on EOLS
About Evolus
(
Get Free Report)
Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
Recommended Stories
Before you consider Evolus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evolus wasn't on the list.
While Evolus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
